Features & Analyses

New rules applicable to Shanghai's Lin-Gang New Area have been released. Wenpei Yu and Yunsi Hu of Lifeng Partners analyze their workings, how they fit into China's existing system of cross-border data transfer rules and why they are so significant for biomedical companies operating in the zone

The amended PRC Company Law will have many, far-reaching effects, including motivating companies to reduce their registered capital in order to optimize capital utilization. Daisy Duan, Yingjie Yang and Cuishi Li of King & Wood Mallesons introduce the motivations and tax implications associated with one possible route: formal capital reductions

Casper Sek, partner of Jingtian & Gongcheng, looks at the unique complexities of providing artificial intelligence services in China: one of the most exciting and fast-moving tech markets in the world

Geoffrey Chan and Angela Liu of Skadden, Arps, Slate, Meagher & Flom in Hong Kong examine key structuring considerations for international companies planning to establish a corporate venture capital arm in China or elsewhere in Asia

Wu Peng, Fang Jianwei, Hou Chuchen and Wang Songyang of Zhong Lun Law Firm in Shanghai set out the highlights of a new judicial interpretation regarding civil disputes relating to an alleged monopoly

Karen R King, partner at Morvillo Abramowitz Grand Iason & Anello P.C., and Jianwei (Jerry) Fang, partner at Zhong Lun Law Firm, describe how U.S. jurisdiction can reach Chinese nationals, and how to mitigate any personal risk

Daisy Duan, Sara Shi and Jinwen Shi of King & Wood Mallesons unpack the tax implications of a new law which overhauls China's system of customs tariffs

Philip Qu and Qiuchen Wang from TransAsia Lawyers analyze a pioneering approach to regulating cross-border data transfers recently adopted in one of Shanghai's free trade zones

Fang Jianwei, Lv Chao and Yuan Chenhao of Zhong Lun Law Firm in Shanghai explain the background and impact – including on multinational companies – of a set of new rules governing the local production of imported drugs